Physician profile
Amit Sharma
NPI 1447564950
$3,567.59
in general payments reported to CMS, 2019-2025
29 companies · $812 in 2025
The $812 reported for 2025 was more than what 82% of Family Medicine providers received nationally (typical 2025 total: $153).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $480 · 2020: $243 · 2021: $417 · 2022: $561 · 2023: $387 · 2024: $668 · 2025: $812.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $1,866.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $1,866.12 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Zoll Services LLC (A/K/A Zoll Lifecor Corp) | $617.07 | 2019-2024 | Lifevest |
| Amgen INC. | $601.42 | 2023-2025 | Otezla, Repatha, Repatha |
| Boehringer Ingelheim Pharmaceuticals, INC. | $357.90 | 2019-2021 | |
| Lilly USA, LLC | $322.82 | 2023-2025 | Zepbound, Mounjaro |
| Abbott Laboratories | $219.81 | 2019-2022 | |
| Astrazeneca Pharmaceuticals LP | $191.27 | 2024-2025 | Airsupra, Breztri |
| Novartis Pharmaceuticals Corporation | $163.18 | 2019-2024 | |
| Lucid Diagnostics INC. | $153.85 | 2022 | |
| Cequr Corporation | $108.96 | 2025 | Cequr Simplicity |
| Abbvie INC. | $104.30 | 2022-2024 | Qulipta, Ubrelvy |
| Allergan, INC. | $100.05 | 2022 | |
| Janssen Pharmaceuticals, INC | $86.98 | 2019-2020 | |
| Insulet Corporation | $70.07 | 2021 | |
| Merck Sharp & Dohme LLC | $66.56 | 2019-2020 | |
| Abiomed | $60.55 | 2025 |
Show all 28 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Glaxosmithkline, LLC. | $48.26 | 2022-2023 | Shingrix, Bexsero |
| Pfizer INC. | $45.63 | 2023-2025 | |
| Corcept Therapeutics | $41.40 | 2025 | Korlym |
| Novo Nordisk INC | $37.17 | 2021-2024 | Wegovy |
| Sonex Health, INC. | $27.50 | 2024 | Sx-One Microknife |
| Medtronic, INC. | $23.19 | 2022 | |
| Xeris Pharmaceuticals, INC. | $21.37 | 2021 | |
| Irhythm Technologies, INC. | $18.04 | 2021 | |
| Otsuka America Pharmaceutical, INC. | $16.78 | 2022 | |
| Exact Sciences Corporation | $16.60 | 2025 | The Cologuard Plus Collection Kit |
| Boston Scientific Corporation | $16.28 | 2022 | |
| Axsome Therapeutics, INC. | $15.31 | 2025 | Auvelity |
| Vifor Pharma, INC. | $15.27 | 2019 |
1 company reported research payments only; those appear in the research section below.
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Amit Sharma listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.